Carboplatin Market Size Worth USD 8.13 Billion by 2025 | CAGR: 5.8%

The carboplatin market is expected to grow at CAGR of 5.8% to reach USD 8.13 billion by 2025.

A chemotherapy drug, carboplatin is an analog of cisplatin. Carboplatin is a radiation-sensitizing cell cycle-phase nonspecific molecule, thus, it is used to treat different types of cancer such as lung and ovarian cancer. It is a second-generation platinum compound with a broad spectrum of tumoricidal and anti-neoplastic properties. This chemical contains a platinum atom complexed with a cyclobutane-dicarboxylic residue and two ammonia molecules. This agent is activated intracellularly in order to form a reactive platinum complex that binds to nucleophilic groups which result in cell growth inhibition.

The exact mechanism of action for this chemical compound is not known. However, it is noted that it undergoes intracellular activation to form reactive platinum which inhibits DNA synthesis by forming intrastrand or interstrand cross-linking DNA molecules. Side effects such as hypersensitivity, hyponatremia, abdominal pain, etc. associated with this chemical will hamper the industry growth to some extent. The worldwide carboplatin research report provides a detailed analysis of the industrial development for the estimation period 2014-2025. The Global Carboplatin market report offers elaborate information about market value, share, growth rate, and future prospects. The study also analyzes the complete value chain the chemical which covers the study of potential market dynamics, enriching business strategies with quality data, sales channels, distributors & supplier analysis, and new introductions with respect to this market.

Browse 51 Tables and 104 Figures spread through over 150 Pages and in-depth TOC on” Carboplatin Market, By Type (Octreotide, Lanreotide, Pasireotide), By Indication and By Region (North America, Europe, Asia Pacific and RoW) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025” Request Sample Here

KEY TAKEAWAYS

• In terms of types, the industry is divided into Carboplatin Crystal and Carboplatin Powder. The crystal segment accounted for the significant revenue share and is growing with a promising growth rate over the study period.
• Depending upon indication, the market is categorized as small cell lung cancer (SSCLC), ovarian cancer, and others. The small cell lung care indication accounted for the significant revenue share in 2018. However, the share of this indication is projected to decline over the study period as the incidence of SCLC has declined considerably in the past year due to the decrease in smoking rates worldwide.
• Regionally, Asia Pacific captured maximum revenue share owing to the rising incidence of cancer, increasing healthcare spending coupled with growing contract manufacturing service in the region
• The proposed report provides key stakeholders with carboplatin manufacturers, main distributors, government/non-government industry associations, and downstream vendors details for regions such as North America, Asia Pacific, Europe, Middle East, and Africa and Latin America
• Teva Pharmaceuticals, Fresenius Kabi, Mylan Laboratories, Taj Pharmaceuticals, Umicore, Johnson Matthey, and Tecoland Corporation are some of the prominent key players in this market

The global Carboplatin market by its major segments, which include as follows:

CARBOPLATIN MARKET, BY ANALOG TYPE

• Octreotide
• Lanreotide
• Pasireotide

CARBOPLATIN MARKET, BY INDICATION

• Acromegaly
• Neuroendocrine Tumour (NET)
• Others

CARBOPLATIN MARKET, BY REGION

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Rest of Europe
• Asia Pacific
  • India
  • China
  • Rest of APAC
• Rest of the World
  • Middle East and Africa
  • Latin America